I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Book ChapterDOI
Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy.
Journal ArticleDOI
Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity
TL;DR: Results indicate that the location of the ligand-protein junction can be selectively moved to enhance conjugate effectiveness, and implications could be made regarding which regions of IL4 are important for binding.
Expression of HER2 in Human Gastric Cancer Cells Directly Correlates with Antitumor Activity of a Recombinant Disulfide-Stabilized
Hisashi Shinohara,Shinsho Morita,Masaru Kawai,Akiko Miyamoto,Toyooki Sonoda,Ira Pastan,Nobuhiko Tanigawa +6 more
TL;DR: It is concluded that an erb-38 anti-HER2 immunotoxin has specific antitumor activities against human gastric cancer cells overexpressing HER2.
Journal ArticleDOI
Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy.
TL;DR: The generation of an amphotropic producer cell line (CA2) that synthesizes viral particles carrying a bicistronic cassette in which the selectable MDR1 cDNA encoding P-glycoprotein a multidrug efflux pump, and the human glucocerebrosidase gene are transcriptionally fused is reported.
Book ChapterDOI
Expression of the MDR1 gene in human cancers.
TL;DR: Although chemotherapy can result in the cure of many malignancies, there are many cancers, such as breast cancer and non-Hodgkins lymphoma, that initially may respond to chemotherapy and then relapse either during or after therapy.